Immunocore Holdings financials
$30.85+0.69%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 |
|---|---|---|---|---|---|
| Revenue | $400.0M | $310.2M | $249.4M | $174.4M | $36.5M |
| Gross profit | $394.9M | $307.5M | $248.4M | $173.3M | $36.5M |
| Gross margin | 98.7% | 99.1% | 99.6% | 99.4% | 100.0% |
| Operating income | -$45.4M | -$70.5M | -$59.6M | -$51.7M | -$174.6M |
| Net income | -$35.5M | -$51.1M | -$55.3M | -$52.5M | -$180.0M |
| Net margin | −8.9% | −16.5% | −22.2% | −30.1% | −493.4% |
| Diluted EPS | $-0.71 | $-1.02 | $-1.13 | $-1.15 | $-4.24 |
| EBITDA | -$42.1M | -$66.3M | -$55.6M | -$46.4M | -$167.0M |
| Operating cash flow | -$10.7M | $26.1M | $2.9M | -$49.2M | -$143.1M |
| Free cash flow | -$15.1M | $20.9M | -$2.5M | -$51.4M | -$144.5M |
| Diluted shares | 50.3M | 50.0M | 48.9M | 45.7M | 42.5M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|
| Cash & equivalents | $467.7M | $455.7M | $442.6M | $402.5M | $316.5M |
| Short-term investments | $396.4M | $364.6M | $0.00 | $0.00 | $0.00 |
| Total debt | $393.1M | $391.0M | $48.0M | $47.8M | $49.5M |
| Total assets | $1.07B | $1.01B | $597.0M | $526.8M | $401.4M |
| Total liabilities | $686.2M | $648.8M | $228.2M | $187.9M | $173.2M |
| Shareholders' equity | $381.0M | $360.7M | $368.8M | $338.9M | $228.2M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology